1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B3D3782552729703002585DD00605D4E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-addyi-flibanserin-how-an-upstart-biopharma-used-social-media-and-policy-tools-to-support-its-NDA-approval?opendocument
18
19opendocument
2054.236.35.159
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Public Relations

Addyi (flibanserin): How an upstart biopharma used social media and policy tools to support its NDA approval - and a $1 billion payday

ID: 5630


Features:

49 Info Graphics

2 Data Graphics

57 Metrics

3 Narratives


Pages/Slides: 62


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Addyi (flibanserin): How an upstart biopharma used social media and policy tools to support its NDA approval - and a $1 billion payday"

STUDY OVERVIEW

Developed in early 2000s for anxiety, flibanserin was repositioned for hyposexual desire disorder in mid-2000s by Boehringer Ingelheim. After initial submission was rejected by FDA in 2010, Sprout Pharma acquired development rights from BI. FDA rejected second clinical submission in 2013 and Sprout used active lobbying, policy and social media campaigns to ensure its NDA was given “full consideration.”

Sprout resubmitted and won FDA approval in 2015 and Addyi (flibanserin) became the first drug approval in HSDD category. Valeant Pharmaceuticals acquired Addyi® for $1 billion one week after FDA approval, but the drug got caught up in problems at Valeant. Sprout buys Addyi® back from Valeant in 2016 and the product is still on the market.

This case study examines how Sprout utilized social media and policy tools to pressure regulators to reconsider previous objections to the drug and to ultimately win approval for Addyi.

KEY TOPICS

  • Introduction: From Rejections to Market Entry
  • Adjusting Clinical Development Plan: Path to Approval
  • Political Pivot: Developing Political Pressure for Drug Review
  • Social Media: Flexible Tool to Inform, Educate and Advocate
  • The Decision: Positive Review from FDA
  • Ongoing Controversy: Debate on Efficacy, Risks and Clinical Data
  • In-Market: Commercial Blues and Future of Addyi
  • Lessons Learned & Winning Strategies
SAMPLE KEY FINDINGS
  • Build Policy on Science: Sprout used medical experts to bring credibility to HSDD and the policy issue regarding unequal treatment of women’s health before the FDA
  • Using Twitter: Twitter is a powerful platform for education and policy campaigns. Even The Score Campaign ran for 2 years, pulled 1989 followers and generated 1286 tweets
METHODOLOGY

This study was developed using extensive secondary research of government and company information.

Industries Profiled:
Pharmaceutical


Companies Profiled:
Boehringer Ingelheim; Sprout Pharmaceuticals; Valeant

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.